Direct oral anticoagulants in patients with cancer

被引：2

作者：

Bossaer, John B. ^{[1
]}

Covert, Kelly L. ^{[1
]}

机构：

[1] East Tennessee State Univ, Bill Gatton Coll Pharm, Mountain Home, TN 37684 USA

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2019年 / 76卷 / 14期

关键词：

anticoagulation; atrial fibrillation; cancer; direct oral anticoagulants; supportive care; venous thromboembolism; VITAMIN-K ANTAGONIST; VENOUS THROMBOEMBOLISM; ATRIAL-FIBRILLATION; ANTITHROMBOTIC THERAPY; SUBGROUP ANALYSIS; CHEST GUIDELINE; RISK-FACTORS; WARFARIN; RIVAROXABAN; APIXABAN;

D O I：

10.1093/ajhp/zxz095

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Purpose This review summarizes the available evidence concerning direct oral anticoagulant (DOAC) use to treat venous thromboembolism (VTE) in patients with cancer as well as pertinent safety data on the use of DOACs in patients with both cancer and atrial fibrillation. Summary The introduction of DOACs into clinical practice changed the way thrombotic complications are managed and prevented in diverse patient populations, including VTE and atrial fibrillation. Low-molecular-weight heparins have been the standard of care for treating VTE in cancer patients due to superiority over vitamin K antagonists in preventing recurrent VTE. Therefore, widespread DOAC use for VTE in patients with active cancer has not been adopted. Conclusion Recent randomized clinical trials (SELECT-D, Hokusai VTE Cancer) have provided evidence that DOACs may have a role in treating VTE in cancer patients.

引用

页码：1019 / 1027

页数：9

共 45 条

[1] Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial [J].

Agnelli, G. ;

Buller, H. R. ;

Cohen, A. ;

Gallus, A. S. ;

Lee, T. C. ;

Pak, R. ;

Raskob, G. E. ;

Weitz, J. I. ;

Yamabe, T. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (12) :2187-2191

[2]

[Anonymous], 2018, AVASTIN BEVACIZUMAB

[3]

[Anonymous], 2012, VOTRIENT PAZOPANIB P

[4]

[Anonymous], 2018, BLOOD S1, DOI DOI 10.1182/BLOOD-2018-99-118808

[5] Malignancies, prothrombotic mutations, and the risk of venous thrombosis [J].

Blom, JW ;

Doggen, CJM ;

Osanto, S ;

Rosendaal, FR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06) :715-722

[6]

Celgene, 2019, REVLIMID LENALIDOMID

[7] The Efficacy and Safety of Rivaroxaban and Dalteparin in the Treatment of Cancer Associated Venous Thrombosis [J].

Chaudhury, Ateefa ;

Balakrishnan, Asha ;

Thai, Christy ;

Holmstrom, Bjorn ;

Nanjappa, Sowmya ;

Ma, Zhenjun ;

Jaglal, Michael, V .

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (03) :530-534

[8] Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKETAF [J].

Chen, Sean T. ;

Hellkamp, Anne S. ;

Becker, Richard C. ;

Berkowitz, Scott D. ;

Breithardt, Guenter ;

Fox, Keith A. A. ;

Hacke, Werner ;

Halperin, Jonathan L. ;

Hankey, Graeme J. ;

Mahaffey, KennethW. ;

Nessel, Christopher C. ;

Piccini, Jonathan P. ;

Singer, Daniel E. ;

Patel, Manesh R. ;

Melloni, Chiara .

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2019, 5 (02) :145-152

[9] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[10] Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study [J].

Donato, Jessica ;

Campigotto, Federico ;

Uhlmann, Erik J. ;

Coletti, Erika ;

Neuberg, Donna ;

Weber, Griffin M. ;

Zwicker, Jeffrey I. .

BLOOD, 2015, 126 (04) :494-499

← 1 2 3 4 5 →